| (210) | Number of the EPO application | 21853586 |
| (220) | Filing date of the EPO application | 2021.08.06 |
| (80) | EPO patent specification publication (B) | EPB nr. 43/2025, 2025.10.22 |
| (110) | EPO patent number | 4192831 |
| (21) | Number of the application | e 2023 0626 |
| (71) | Name(s) of applicant(s), code of the country | Gasherbrum Bio, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | MENG Qinghua, CN;
LEI Hui, CN;
ZHANG Haizhen, CN;
LIN Xichen, CN;
JENNINGS Andrew, US; |
| (73) | Name(s) of owner(s), code of the country | Gasherbrum Bio, Inc., US; |
| (54) | Title of the invention | HETEROCYCLIC GLP-1 AGONISTS |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 413/14 (2006.01.01); C07D 413/00 (2006.01.01); C07D 405/14 (2006.01.01); C07D 405/12 (2006.01.01); A61K 31/496 (2006.01.01); A61P 3/10 (2006.01.01) |
| (52) | Cooperative Patent Classification | C07D 401/14 (EP); A61K 31/155 (EP); A61K 31/454 (EP); A61K 31/4545 (EP); A61K 31/496 (EP); A61K 31/506 (EP); A61K 45/06 (EP); A61P 3/10 (EP); C07D 405/14 (EP); C07D 409/14 (EP); C07D 413/14 (EP); C07D 417/14 (EP) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2023.07.31 |
| (30) | Priority | PCT/CN2020/1074, 2020.08.06, WO; PCT/CN2021/0739, 2021.01.27, WO |
| (86) | International application | PCT/CN2021/111193, 2021.08.06 |
| (87) | International publication | WO 2022/028572, 2022.02.10 |